NEW YORK, NY / ACCESSNEWSWIRE / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

PLANEGG-MARTINSRIED, Germany I, 2025 I Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

Law Offices of Howard G. Smith reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Regeneron ...

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Regeneron stock fell slightly Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).